The Trump administration has initiated a new crackdown on fraud within federal health benefits programs, specifically targeting health insurers and pharmacy benefit managers (PBMs), according to Fox News Digital [1]. The Office of Personnel Management (OPM), in collaboration with the White House Task Force to Eliminate Fraud, is issuing new compliance directives to insurance carriers participating in the Federal Employees Health Benefits (FEHB) and Postal Service Health Benefits programs. These directives require insurers to enhance fraud prevention measures, conduct more rigorous payment reviews, strengthen pharmacy benefit oversight, increase subcontractor accountability, and improve audits and reporting processes [1].
The FEHB program, which cost taxpayers approximately $70 billion and covered over 8.2 million federal employees, family members, and other eligible individuals in fiscal year 2024, is a significant focus of this initiative [1]. The Government Accountability Office (GAO) highlighted in a July 2025 report that OPM needed to do more to manage fraud risks in the FEHB program, citing vulnerabilities such as benefit card sharing, improper inducements, fraudulent documentation, kickbacks, marketing fraud, theft of personally identifiable information, provider ineligibility, and self-referrals [1].
To address these risks, OPM is establishing a data science and audit team in partnership with the agency’s inspector general. This team will proactively review anonymized claims data to detect fraud, waste, and overbilling [1]. The crackdown also extends to PBMs, the intermediaries responsible for administering prescription drug benefits and negotiating with drugmakers and pharmacies [1].
White House Task Force Executive Director Scott Brady stated, “OPM is a valuable partner and leader on the Task Force. The steps taken today will protect taxpayers and our federal workforce” [1]. The announcement follows a broader federal effort to address fraud in medical programs, including a nationwide probe into Medicaid [1].
CONCLUSION
The Trump administration’s new directives represent a significant escalation in efforts to combat fraud within federal health benefits programs, with a particular focus on insurers and pharmacy benefit managers. By tightening compliance and oversight, the administration aims to protect taxpayer funds and federal employees. The market impact is medium, as these measures could affect the operations and compliance costs of insurers and PBMs involved in federal programs.